海森药业 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	472.0M	397.0M	423.0M	389.0M	285.0M
Revenue Growth %	18.9%	-6.1%	8.7%	36.5%	--
Total Revenue	472.0M	397.0M	423.0M	389.0M	285.0M
Cost Of Revenue	276.0M	234.0M	265.0M	233.0M	173.0M
+Gross Profit	196.0M	163.0M	158.0M	156.0M	112.0M
Gross Margin %	41.5%	41.1%	37.4%	40.1%	39.3%
Total Operating Cost	337.0M	281.0M	306.0M	285.0M	217.0M
Selling Expenses	12.4M	10.5M	10.0M	9.5M	10.5M
Admin Expenses	30.7M	26.0M	22.7M	24.2M	17.2M
Rd Expenses	27.8M	18.8M	15.8M	12.1M	10.8M
Finance Expenses	-18.1M	-15.9M	-11.6M	978,600	3.4M
+Operating Income	142.0M	122.0M	122.0M	109.0M	74.0M
Operating Margin %	30.1%	30.7%	28.8%	28.0%	26.0%
Non Operating Income	1.2M	8,700	4.0M	702,500	133,500
Non Operating Expenses	1.5M	1.3M	1.9M	1.1M	540,600
Investment Income	3.0M	319,700	-3.1M	710,800	3.6M
Fair Value Change Income	--	--	-740,300	740,300	--
Asset Disposal Income	--	-241,700	--	--	--
Asset Impairment Loss	3.5M	2.4M	1.2M	1.9M	585,400
Other Income	4.2M	5.0M	8.6M	3.6M	2.9M
Income Before Tax	142.0M	121.0M	124.0M	109.0M	73.6M
Income Tax	19.2M	16.0M	16.2M	14.5M	10.7M
+Net Income	123.0M	105.0M	108.0M	94.0M	62.8M
Net Margin %	26.1%	26.4%	25.5%	24.2%	22.0%
Net Income Attributable	123.0M	105.0M	108.0M	94.0M	62.8M
Eps Basic	1.22	1.13	2.11	1.84	1.23
Eps Diluted	1.21	1.13	2.11	1.84	1.23

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	1.0B	944.0M	247.0M	205.0M	140.0M
Trading Financial Assets	--	--	--	740,300	--
Accounts Receivable	53.5M	51.7M	43.6M	22.8M	27.9M
Notes Receivable	4.3M	2.6M	--	--	--
Notes And Accounts Receivable	57.8M	54.3M	43.6M	22.8M	27.9M
Prepayments	3.3M	2.3M	2.7M	1.1M	890,300
Inventory	115.0M	159.0M	143.0M	105.0M	86.2M
Total Current Assets	1.3B	1.2B	446.0M	361.0M	267.0M
Fixed Assets	--	86.3M	76.3M	83.6M	58.4M
Fixed Assets Total	120.0M	86.3M	76.3M	83.6M	58.4M
Construction In Progress	--	42.4M	8.4M	929,200	6.2M
Construction In Progress Total	73.6M	48.1M	8.4M	929,200	6.2M
Intangible Assets	20.1M	19.8M	19.7M	20.3M	18.1M
Long Term Deferred Expenses	265,800	257,500	1.8M	3.3M	5.0M
Total Non Current Assets	228.0M	163.0M	119.0M	117.0M	96.4M
Total Assets	1.5B	1.3B	566.0M	477.0M	363.0M
Short Term Borrowings	--	--	--	--	--
Accounts Payable	52.2M	32.6M	19.0M	17.4M	21.1M
Advance Receipts	--	--	--	--	122,300
Contract Liabilities	7.9M	4.2M	7.1M	9.5M	5.6M
Total Current Liabilities	122.0M	78.8M	83.4M	103.0M	77.1M
Total Non Current Liabilities	19.8M	12.8M	13.2M	13.2M	7.3M
Total Liabilities	142.0M	91.6M	96.6M	116.0M	84.4M
Paid In Capital	103.0M	68.0M	51.0M	51.0M	51.0M
Capital Reserve	760.0M	763.0M	104.0M	104.0M	104.0M
Surplus Reserve	54.4M	41.7M	41.7M	30.9M	21.5M
Retained Earnings	451.0M	375.0M	271.0M	174.0M	101.0M
Equity Attributable	1.3B	1.2B	469.0M	361.0M	279.0M
Total Equity	1.3B	1.2B	469.0M	361.0M	279.0M

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	364.0M	301.0M	311.0M	295.0M	216.0M
Tax Refunds Received	--	2.0M	4.8M	4.2M	4.0M
Total Operating Cash Inflow	387.0M	326.0M	335.0M	310.0M	227.0M
Cash Paid For Goods	97.8M	121.0M	169.0M	113.0M	70.4M
Cash Paid To Employees	70.2M	63.4M	59.8M	49.5M	41.5M
Taxes Paid	19.3M	35.4M	10.0M	17.1M	14.0M
Total Operating Cash Outflow	219.0M	245.0M	260.0M	203.0M	150.0M
Operating Cash Flow	167.0M	80.6M	74.9M	107.0M	76.5M
Total Investing Cash Inflow	373.0M	80.4M	2.1M	108.0M	310.0M
Total Investing Cash Outflow	435.0M	137.0M	23.3M	143.0M	282.0M
Investing Cash Flow	-61.7M	-57.0M	-21.2M	-34.5M	27.8M
Cash From Borrowings	--	--	--	--	--
Dividends And Interest Paid	34.0M	--	712,900	16.4M	53.9M
Debt Repayments	--	--	--	--	--
Total Financing Cash Inflow	25.5M	698.0M	--	--	--
Total Financing Cash Outflow	35.9M	25.1M	3.8M	18.7M	53.9M
Financing Cash Flow	-10.4M	673.0M	-3.8M	-18.7M	-53.9M
Net Change In Cash	97.7M	698.0M	55.5M	52.3M	48.5M
Ending Cash Balance	1.0B	937.0M	239.0M	184.0M	131.0M
Capex	64.7M	57.4M	20.2M	33.3M	21.0M